A novel hemostatic delivery device for thrombin: biodegradable poly(D,L-lactide-co-glycolide) 50:50 microspheres.
Standard
A novel hemostatic delivery device for thrombin: biodegradable poly(D,L-lactide-co-glycolide) 50:50 microspheres. / Smeets, Ralf; Gerhards, Frank; Stein, Jamal M; Stein, Jamal; Paz, Rui Miguel Pereira; Vogt, Stephan; Pautke, Christoph; Weitz, Jochen; Kolk, Andreas.
In: J BIOMED MATER RES A, Vol. 96, No. 1, 1, 2011, p. 177-185.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A novel hemostatic delivery device for thrombin: biodegradable poly(D,L-lactide-co-glycolide) 50:50 microspheres.
AU - Smeets, Ralf
AU - Gerhards, Frank
AU - Stein, Jamal M
AU - Stein, Jamal
AU - Paz, Rui Miguel Pereira
AU - Vogt, Stephan
AU - Pautke, Christoph
AU - Weitz, Jochen
AU - Kolk, Andreas
PY - 2011
Y1 - 2011
N2 - Topical thrombins are locally active hemostatic agents that can be used to minimize blood loss during any surgery. The aim of this study was to design and investigate a thrombin-containing biodegradable hemostyptic device with an optimized drug release profile to promote local blood clot formation. It is effective with ongoing systemic antithrombotic therapy and can be used in all types of bone-related surgery, for example, in dental surgery. Thrombin-loaded poly(D,L-lactide-co-glycolide) microspheres were synthesized by means of complex (w/o/w) emulsion evaporation method. The resulting enzyme activity of the serine-protease thrombin was verified by the specific chromogenic substrate S-2238. The thrombin release profile depended on four factors: (1) thrombin dosage, (2) polymer concentration in the o-phase, (3) phase quotient w1:0 in the primary emulsion, and (4) the addition of pore-introducing agents. A collagenous sponge containing thrombin-loaded microspheres by means of lyophilization was developed. The impact of several production factors of the (w1/o/w2) solvent evaporation method to optimize thrombin encapsulation, morphology of the spheres, and desired drug release profile have been investigated. The in vitro thrombin release was dependent on the polymer-to-oil phase ratio, the polymer concentration, and the type of solvent and polymer. The porosity of the spheres and release rate of the active agent were enhanced by increasing the inner aqueous w1 phase. With this study, a new biodegradable hemostyptic device could be verified and established for a potentially safe and locally controlled thrombin release to manage postsurgical hemorrhage in patients undergoing anticoagulant therapy.
AB - Topical thrombins are locally active hemostatic agents that can be used to minimize blood loss during any surgery. The aim of this study was to design and investigate a thrombin-containing biodegradable hemostyptic device with an optimized drug release profile to promote local blood clot formation. It is effective with ongoing systemic antithrombotic therapy and can be used in all types of bone-related surgery, for example, in dental surgery. Thrombin-loaded poly(D,L-lactide-co-glycolide) microspheres were synthesized by means of complex (w/o/w) emulsion evaporation method. The resulting enzyme activity of the serine-protease thrombin was verified by the specific chromogenic substrate S-2238. The thrombin release profile depended on four factors: (1) thrombin dosage, (2) polymer concentration in the o-phase, (3) phase quotient w1:0 in the primary emulsion, and (4) the addition of pore-introducing agents. A collagenous sponge containing thrombin-loaded microspheres by means of lyophilization was developed. The impact of several production factors of the (w1/o/w2) solvent evaporation method to optimize thrombin encapsulation, morphology of the spheres, and desired drug release profile have been investigated. The in vitro thrombin release was dependent on the polymer-to-oil phase ratio, the polymer concentration, and the type of solvent and polymer. The porosity of the spheres and release rate of the active agent were enhanced by increasing the inner aqueous w1 phase. With this study, a new biodegradable hemostyptic device could be verified and established for a potentially safe and locally controlled thrombin release to manage postsurgical hemorrhage in patients undergoing anticoagulant therapy.
KW - Humans
KW - Materials Testing
KW - Microscopy, Electron, Scanning
KW - Particle Size
KW - Absorbable Implants
KW - Biocompatible Materials/chemistry/metabolism
KW - Drug Carriers/chemical synthesis/chemistry/metabolism
KW - Hemostatics/chemistry/metabolism
KW - Hydrogen-Ion Concentration
KW - Lactic Acid/chemistry
KW - Microspheres
KW - Polyglycolic Acid/chemistry
KW - Solvents
KW - Thrombin/chemistry/metabolism
KW - Humans
KW - Materials Testing
KW - Microscopy, Electron, Scanning
KW - Particle Size
KW - Absorbable Implants
KW - Biocompatible Materials/chemistry/metabolism
KW - Drug Carriers/chemical synthesis/chemistry/metabolism
KW - Hemostatics/chemistry/metabolism
KW - Hydrogen-Ion Concentration
KW - Lactic Acid/chemistry
KW - Microspheres
KW - Polyglycolic Acid/chemistry
KW - Solvents
KW - Thrombin/chemistry/metabolism
M3 - SCORING: Journal article
VL - 96
SP - 177
EP - 185
JO - J BIOMED MATER RES A
JF - J BIOMED MATER RES A
SN - 1549-3296
IS - 1
M1 - 1
ER -
